Advertisement
Canada markets closed

  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CAD/USD

    0.7261
    -0.0003 (-0.04%)
     

  • CRUDE OIL

    82.58
    -0.15 (-0.18%)
     

  • Bitcoin CAD

    87,596.42
    +2,686.29 (+3.16%)
     

  • CMC Crypto 200

    1,312.48
    +426.95 (+48.21%)
     

  • GOLD FUTURES

    2,394.20
    -3.80 (-0.16%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     

  • NASDAQ futures

    17,521.00
    -26.25 (-0.15%)
     

  • VOLATILITY

    18.00
    -0.21 (-1.15%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     

  • CAD/EUR

    0.6821
    0.0000 (0.00%)
     

Otezla: Shoring Up Celgene’s Top Line

Kenneth Smith
Updated
Otezla: Shoring Up Celgene’s Top Line

Celgene Corporation (CELG) is an integrated global biopharmaceutical company focused on innovative therapies for treating cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology, and neuroinflammation. Celgene’s Otezla is an oral small molecule inhibitor of PDE4. Otezla has been approved for the treatment of psoriatic arthritis and psoriasis in the United States, Japan, the European Union, and other international markets.

Continue reading